Obesity research & clinical practiceOct 6, 2026

Changes over time in use of diabetes medications during pregnancy in Manitoba, Canada, 2015-2023

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated Oct 7, 2026

Abstract

SGLT2 inhibitor dispensing rose from 1.05 per 1000 pregnancies in 2016 to 2.40 in 2022.

GLP-1 receptor agonist dispensing increased significantly from 0.44 per 1000 pregnancies in 2021 to 3.72 in 2023.
In 2022, dispensing of either SGLT2 inhibitors or GLP-1 receptor agonists was 3.37 per 1000 pregnancies.
The overall dispensing of these medications remained low but showed a trend of increase over the observed period.

Simplified

GLP-1 receptor agonists (GLP-1 RAs) and SGLT2 inhibitors are widely prescribed for type 2 diabetes and cardiometabolic conditions. Using population-based Manitoba administrative health data, we retrospectively examined yearly dispensing trends across 171,103 pregnancies between January 2015 and March 2023. SGLT2 inhibitor dispensing rose from 1.05 per 1000 pregnancies in 2016 to 2.40 in 2022, while GLP-1 RA dispensing increased from 0.44 in 2021 to 3.72 in 2023, indicating a marked recent increase for GLP-1 RAs. Dispensing of either medication class was 3.37 per 1000 pregnancies in 2022. We found that although dispensing of these medications was low, it increased over time.

Full Text

Full text is available at the source.

View Full Text ↗

Changes over time in use of diabetes medications during pregnancy in Manitoba, Canada, 2015-2023

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief